Archives
What High-Yield Rabbit Pharming Evidence Shows
2026-11-18
A targeted rabbit line produced unusually high concentrations of a reporter protein in milk, but the result is a proof of concept rather than a controlled demonstration that the same performance will generalize to therapeutic proteins or manufacturing-scale output.
What High-Yield Rabbit Pharming Evidence Shows
2026-11-18
A targeted CSN2-locus strategy produced unusually high reporter-protein concentrations in rabbit milk, but the result supports a promising expression architecture rather than a validated general platform for therapeutic manufacturing.
How CSN2 Targeting Raises Rabbit Pharming Yield
2026-11-17
A literature-focused analysis of how endogenous CSN2 regulation, targeted insertion, and allele inheritance shaped the reported increase in recombinant protein concentration in rabbit milk. The evidence is promising but remains centered on a fluorescent reporter and a limited set of animals, so its industrial and therapeutic implications require careful qualification.
How Endogenous Milk Promoters Raise Pharming Yield
2026-11-17
A 2025 rabbit study links targeted insertion at the endogenous CSN2 milk-protein locus with unusually high tdTomato concentrations in milk. The findings support a mechanistic model in which tissue-specific regulatory context and controlled transgene placement reduce some sources of expression variability. They do not yet establish equivalent performance for therapeutic proteins, total lactational output, product quality, or platform-wide reproducibility.
SCP4 and the Control of Mitotic Fidelity
2026-11-16
The cited study identifies SCP4 as a phosphatase that counterbalances Haspin-dependent H3T3 phosphorylation and links this activity to chromosomal passenger complex recruitment, chromosome segregation, and genomic stability. Its evidence spans phosphatase screening, cellular perturbation, biochemical validation, and developmental observations, while 2-Thio-dCTP belongs to a separate DNA-centered research context.
What CSN2 Targeting Shows in Rabbit Pharming
2026-11-16
A targeted knock-in strategy linked the rabbit CSN2 milk-protein locus to a reported tdTomato concentration of 15–20 g/L in milk from two homozygous animals. The result is a strong proof of concept for locus- and promoter-aware expression, but it does not yet establish equivalent performance for therapeutic proteins or industrial production.
Hematoxylin and Neonatal Uterine Development
2026-11-15
Hematoxylin functions here as a nuclear stain within the tissue-visualization layer of a neonatal pig study. The biological evidence links naturally low early-life immunoglobulin transfer with altered uterine glandularity, FOXA2 expression, immune signaling, and developmental gene programs, while leaving antibody-specific causality and long-term persistence unresolved.
What CMC Determines in mRNA–LNP Translation
2026-11-14
A literature-focused interpretation of how lipid chemistry, manufacturing comparability, analytical controls and physiological stability shape the translation of mRNA lipid nanoparticles from proof of concept to clinically credible products.
A Targeted Locus Reframes Rabbit Pharming Yields
2026-11-13
A 2025 rabbit study links targeted insertion at the endogenous CSN2 locus with markedly higher reporter-protein concentrations in milk, while leaving important questions about generalizability, product quality, reproducibility, and manufacturing performance unresolved.
How the CSN2 Locus Changes Rabbit Pharming
2026-11-13
A literature-focused analysis of a 2025 study that used a defined CSN2-locus knock-in strategy to raise reporter-protein concentrations in rabbit milk. The findings are notable but remain bounded by a small production cohort, a reporter rather than a therapeutic protein, and comparisons with heterogeneous historical datasets.
Why CSN2 Targeting Raises Rabbit Pharming Yield
2026-11-12
A mechanistic analysis of how targeting the endogenous CSN2 milk-protein locus may improve recombinant protein concentration in rabbit milk, what the reported tdTomato findings establish, and where the evidence remains limited.
Rabbit Pharming: What the Yield Comparison Shows
2026-11-12
A 2025 study reported 15–20 g/L of a reporter protein in milk from two homozygous knock-in rabbits, substantially above historical yields. The finding supports the feasibility of endogenous-locus targeting, but its causal mechanism, product generalizability, and comparative magnitude remain unresolved.
A Targeted Strategy for Rabbit Milk Pharming
2026-11-11
A 2025 study used targeted integration at the rabbit CSN2 locus to drive reporter-protein expression from an endogenous milk-protein regulatory context. The resulting homozygous animals produced 15–20 g/L tdTomato in milk, but the evidence remains a reporter-based proof of concept rather than a direct demonstration of therapeutic-product quality, process performance, or generalizability.
Why Context Changes a Research Result
2026-11-11
A reported protein concentration acquires meaning from the model, genetic design, comparator, and measurement context around it. The rabbit pharming study illustrates why an impressive milk concentration can support a proof of concept without establishing therapeutic equivalence, manufacturing consistency, or broad transferability.
What High-Yield Rabbit Pharming Actually Shows
2026-11-10
A targeted rabbit line produced unusually high tdTomato concentrations in milk, but the evidence remains a proof of concept rather than a matched demonstration that promoter choice alone determines therapeutic-protein output.